Navigation Links
The Leukemia & Lymphoma Society Awards Major Grant to Stanford Researcher
Date:9/30/2008

LLS Specialized Center of Research Program Hits $178 Million Mark

WHITE PLAINS, N.Y., Sept. 30 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded a new Marshall A. Lichtman Specialized Center of Research (SCOR) grant to Beverly Mitchell, M.D., George E. Becker Professor of Medicine at Stanford University.

Dr. Mitchell and her team will receive $1.25 million a year for five years, for a total of $6.25 million. The SCOR program is LLS's largest research grant, with total funding of $178.25 million since its inception in 2000. The title of her SCOR is: Molecular and Cellular Characterization of Myelodysplastic Syndromes.

The SCOR program brings together teams of researchers representing different disciplines in collaborative efforts to discover new approaches to treat patients with leukemia, lymphoma and myeloma. Awards go to groups that best demonstrate outstanding scientific promise facilitated by the synergy that will occur from their combined efforts.

Dr. Mitchell's team is studying stem cells in myelodysplastic syndromes (MDS), a collection of related disorders in which damaged bone marrow cells can't mature into functional blood cells. The disorders frequently progress to acute myelogenous leukemia (AML). Her team has recently identified new molecular markers than can help identify the MDS stem cells that have progressed to AML, and are working to develop therapies to target these abnormal MDS stem cells. A clinical trial of an investigational drug that targets one of the enzymes involved in the development of MDS will be initiated.

"Dr. Mitchell and her team of investigators are undertaking cutting-edge research to reach a better understanding of the root causes of MDS," said Louis DeGennaro, Ph.D., LLS's chief scientific officer. "Their work will likely lead to new therapies that target these diseases. This research team is an impressive addition to the outstanding scientists already in the SCOR program."

SCOR is one of three integrated research grant programs established by LLS. These also include the Career Development Program, which provides stipends to investigators of exceptional promise in the early stages of their careers; and the Translational Research Program, which encourages and supports outstanding research with strong promise of translating emerging biomedical knowledge into new treatments. In addition, the Therapy Acceleration Program is designed to help move potential therapies more quickly through the development pipeline.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $600 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 6.3 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call LLS's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.
Andrea Greif

914-821-8958

andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New leukemia signal could point way to better treatment, Stanford researchers find
2. The Leukemia & Lymphoma Society: Standing Up to Cancer for 60 Years
3. Stater Bros. Raises $200,000 for the Leukemia & Lymphoma Society
4. Methadone Kills Resistant Leukemia Cells
5. FDA Accepts Gentas NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia
6. Leukemia drug could save lives of stroke patients
7. Math could help cure leukemia
8. Gene mutation improves leukemia drugs effect
9. Microenvironment a main driver of aggressive multi-lineage leukemia disease type
10. Clinical study shows biological and clinical activity in relapsed leukemia patients
11. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
Breaking Medicine Technology: